tiprankstipranks
Neurocrine Biosciences (NBIX)
NASDAQ:NBIX
US Market
NBIX
Neurocrine
RESEARCH TOOLSreports
Want to see NBIX full AI Analyst Report?

Neurocrine (NBIX) Stock Forecast & Price Target

1,639 Followers
See the Price Targets and Ratings of:

NBIX Analyst Ratings

Strong Buy
26Ratings
Strong Buy
23 Buy
3 Hold
0 Sell
Based on 26 analysts giving stock ratings to
Neurocrine
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NBIX Stock 12 Month Forecast

Average Price Target

$210.60
▲(19.82% Upside)
Based on 26 Wall Street analysts offering 12 month price targets for Neurocrine in the last 3 months. The average price target is $210.60 with a high forecast of $249.00 and a low forecast of $165.00. The average price target represents a 19.82% change from the last price of $175.77.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"127":"$127","250":"$250","157.75":"$157.8","188.5":"$188.5","219.25":"$219.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":249,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$249.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":210.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$210.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":165,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$165.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[127,157.75,188.5,219.25,250],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,166.8,173.12307692307692,179.44615384615386,185.76923076923077,192.0923076923077,198.41538461538462,204.73846153846154,211.06153846153848,217.3846153846154,223.7076923076923,230.03076923076924,236.35384615384615,242.67692307692306,{"y":249,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,166.8,170.16923076923078,173.53846153846155,176.90769230769232,180.27692307692308,183.64615384615385,187.01538461538462,190.3846153846154,193.75384615384615,197.12307692307692,200.4923076923077,203.86153846153846,207.23076923076923,{"y":210.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,166.8,166.66153846153847,166.52307692307693,166.3846153846154,166.24615384615385,166.1076923076923,165.96923076923076,165.83076923076925,165.6923076923077,165.55384615384617,165.41538461538462,165.27692307692308,165.13846153846154,{"y":165,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":128.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.21,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.88,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.83,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.63,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.38,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.56,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.78,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":161,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.77,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.8,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$249.00Average Price Target$210.60Lowest Price Target$165.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Evercore ISI Analyst forecast on NBIX
Cory Kasimov
Evercore ISI
Evercore ISI
$210→$215
Buy
22.32%
Upside
Reiterated
08/17/26
Analysts Offer Insights on Healthcare Companies: OmniAb (NASDAQ: OABI), Neurocrine (NASDAQ: NBIX) and Evaxion Biotech (NASDAQ: EVAX)
BMO Capital Analyst forecast on NBIX
Evan Seigerman
BMO Capital
BMO Capital
$190
Hold
8.10%
Upside
Reiterated
08/17/26
Neurocrine (NBIX) Gets a Hold from BMO Capital
Morgan Stanley Analyst forecast on NBIX
Sean Laaman
Morgan Stanley
Morgan Stanley
$196→$182
Hold
3.54%
Upside
Assigned
08/13/26
Morgan Stanley Remains a Hold on Neurocrine (NBIX)
Deutsche Bank Analyst forecast on NBIX
David Hoang
Deutsche Bank
Deutsche Bank
$190→$165
Hold
-6.13%
Downside
Assigned
08/13/26
Deutsche Bank Sticks to Its Hold Rating for Neurocrine (NBIX)
Bernstein Analyst forecast on NBIX
Jeffrey Walch
Bernstein
Bernstein
$221→$218
Buy
24.03%
Upside
Reiterated
08/12/26
Analysts' Top Healthcare Picks: Neurocrine (NBIX), Aquestive Therapeutics (AQST)
J.P. Morgan Analyst forecast on NBIX
Anupam Rama
J.P. Morgan
J.P. Morgan
$185→$217
Buy
23.46%
Upside
Reiterated
08/06/26
J.P. Morgan Reaffirms Their Buy Rating on Neurocrine (NBIX)
Wedbush Analyst forecast on NBIX
Laura Chico
Wedbush
Wedbush
$185→$194
Buy
10.37%
Upside
Reiterated
08/03/26
Neurocrine price target raised to $194 from $185 at WedbushNeurocrine price target raised to $194 from $185 at Wedbush
Truist Financial Analyst forecast on NBIX
Danielle Brill
Truist Financial
Truist Financial
$213
Buy
21.18%
Upside
Reiterated
08/03/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY), Neurocrine (NASDAQ: NBIX) and Genmab (NASDAQ: GMAB)
Citi Analyst forecast on NBIX
Yigal Nochomovitz
Citi
Citi
$246→$249
Buy
41.66%
Upside
Reiterated
08/03/26
Neurocrine price target raised to $249 from $246 at CitiNeurocrine price target raised to $249 from $246 at Citi
Canaccord Genuity Analyst forecast on NBIX
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$200→$210
Buy
19.47%
Upside
Reiterated
08/03/26
Neurocrine (NBIX) Receives a Buy from Canaccord Genuity
William Blair Analyst forecast on NBIX
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
07/31/26
Neurocrine Biosciences: Strong Q2 Execution, Expanded Pipeline, and Multi-Billion-Dollar Peak Sales Potential Support Buy Rating
Needham Analyst forecast on NBIX
Ami Fadia
Needham
Needham
$200→$204
Buy
16.06%
Upside
Assigned
07/31/26
Neurocrine Biosciences: Strong Q2 Beat, Upgraded Outlook, and Price Target Raised to $204 Support Buy Rating
Guggenheim Analyst forecast on NBIX
Yatin Suneja
Guggenheim
Guggenheim
$200→$222
Buy
26.30%
Upside
Reiterated
07/31/26
Neurocrine price target raised to $222 from $200 at GuggenheimNeurocrine price target raised to $222 from $200 at Guggenheim
H.C. Wainwright Analyst forecast on NBIX
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$215
Buy
22.32%
Upside
Reiterated
07/31/26
Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), Omnicell (NASDAQ: OMCL) and Guardant Health (NASDAQ: GH)
Oppenheimer Analyst forecast on NBIX
Jay Olson
Oppenheimer
Oppenheimer
$230
Buy
30.85%
Upside
Reiterated
07/31/26
Oppenheimer Sticks to Their Buy Rating for Neurocrine (NBIX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Evercore ISI Analyst forecast on NBIX
Cory Kasimov
Evercore ISI
Evercore ISI
$210→$215
Buy
22.32%
Upside
Reiterated
08/17/26
Analysts Offer Insights on Healthcare Companies: OmniAb (NASDAQ: OABI), Neurocrine (NASDAQ: NBIX) and Evaxion Biotech (NASDAQ: EVAX)
BMO Capital Analyst forecast on NBIX
Evan Seigerman
BMO Capital
BMO Capital
$190
Hold
8.10%
Upside
Reiterated
08/17/26
Neurocrine (NBIX) Gets a Hold from BMO Capital
Morgan Stanley Analyst forecast on NBIX
Sean Laaman
Morgan Stanley
Morgan Stanley
$196→$182
Hold
3.54%
Upside
Assigned
08/13/26
Morgan Stanley Remains a Hold on Neurocrine (NBIX)
Deutsche Bank Analyst forecast on NBIX
David Hoang
Deutsche Bank
Deutsche Bank
$190→$165
Hold
-6.13%
Downside
Assigned
08/13/26
Deutsche Bank Sticks to Its Hold Rating for Neurocrine (NBIX)
Bernstein Analyst forecast on NBIX
Jeffrey Walch
Bernstein
Bernstein
$221→$218
Buy
24.03%
Upside
Reiterated
08/12/26
Analysts' Top Healthcare Picks: Neurocrine (NBIX), Aquestive Therapeutics (AQST)
J.P. Morgan Analyst forecast on NBIX
Anupam Rama
J.P. Morgan
J.P. Morgan
$185→$217
Buy
23.46%
Upside
Reiterated
08/06/26
J.P. Morgan Reaffirms Their Buy Rating on Neurocrine (NBIX)
Wedbush Analyst forecast on NBIX
Laura Chico
Wedbush
Wedbush
$185→$194
Buy
10.37%
Upside
Reiterated
08/03/26
Neurocrine price target raised to $194 from $185 at WedbushNeurocrine price target raised to $194 from $185 at Wedbush
Truist Financial Analyst forecast on NBIX
Danielle Brill
Truist Financial
Truist Financial
$213
Buy
21.18%
Upside
Reiterated
08/03/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY), Neurocrine (NASDAQ: NBIX) and Genmab (NASDAQ: GMAB)
Citi Analyst forecast on NBIX
Yigal Nochomovitz
Citi
Citi
$246→$249
Buy
41.66%
Upside
Reiterated
08/03/26
Neurocrine price target raised to $249 from $246 at CitiNeurocrine price target raised to $249 from $246 at Citi
Canaccord Genuity Analyst forecast on NBIX
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$200→$210
Buy
19.47%
Upside
Reiterated
08/03/26
Neurocrine (NBIX) Receives a Buy from Canaccord Genuity
William Blair Analyst forecast on NBIX
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
07/31/26
Neurocrine Biosciences: Strong Q2 Execution, Expanded Pipeline, and Multi-Billion-Dollar Peak Sales Potential Support Buy Rating
Needham Analyst forecast on NBIX
Ami Fadia
Needham
Needham
$200→$204
Buy
16.06%
Upside
Assigned
07/31/26
Neurocrine Biosciences: Strong Q2 Beat, Upgraded Outlook, and Price Target Raised to $204 Support Buy Rating
Guggenheim Analyst forecast on NBIX
Yatin Suneja
Guggenheim
Guggenheim
$200→$222
Buy
26.30%
Upside
Reiterated
07/31/26
Neurocrine price target raised to $222 from $200 at GuggenheimNeurocrine price target raised to $222 from $200 at Guggenheim
H.C. Wainwright Analyst forecast on NBIX
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$215
Buy
22.32%
Upside
Reiterated
07/31/26
Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), Omnicell (NASDAQ: OMCL) and Guardant Health (NASDAQ: GH)
Oppenheimer Analyst forecast on NBIX
Jay Olson
Oppenheimer
Oppenheimer
$230
Buy
30.85%
Upside
Reiterated
07/31/26
Oppenheimer Sticks to Their Buy Rating for Neurocrine (NBIX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Neurocrine

3 Months
Jay OlsonOppenheimer
Success Rate
17/26 ratings generated profit
65%
Average Return
+3.54%
Copying Jay Olson's trades and holding each position for 3 Months would result in 65.38% of your transactions generating a profit, with an average return of +3.54% per trade.
1 Year
Tazeen AhmadBank of America Securities
Success Rate
14/19 ratings generated profit
74%
Average Return
+6.32%
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 73.68% of your transactions generating a profit, with an average return of +6.32% per trade.
2 Years
Tazeen AhmadBank of America Securities
Success Rate
16/19 ratings generated profit
84%
Average Return
+14.34%
Copying Tazeen Ahmad's trades and holding each position for 2 Years would result in 84.21% of your transactions generating a profit, with an average return of +14.34% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NBIX Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
10
7
8
4
1
Buy
27
26
30
44
36
Hold
6
8
8
8
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
43
41
46
56
45
In the current month, NBIX has received 37 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. NBIX average Analyst price target in the past 3 months is 210.60.
Each month's total comprises the sum of three months' worth of ratings.

NBIX Financial Forecast

NBIX Earnings Forecast

Next quarter’s earnings estimate for NBIX is $1.90 with a range of $1.33 to $2.38. The previous quarter’s EPS was $1.39. NBIX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year NBIX has Performed in-line its overall industry.
Next quarter’s earnings estimate for NBIX is $1.90 with a range of $1.33 to $2.38. The previous quarter’s EPS was $1.39. NBIX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year NBIX has Performed in-line its overall industry.

NBIX Sales Forecast

Next quarter’s sales forecast for NBIX is $1.04B with a range of $1.01B to $1.10B. The previous quarter’s sales results were $959.00M. NBIX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year NBIX has Performed in-line its overall industry.
Next quarter’s sales forecast for NBIX is $1.04B with a range of $1.01B to $1.10B. The previous quarter’s sales results were $959.00M. NBIX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year NBIX has Performed in-line its overall industry.

NBIX Stock Forecast FAQ

What is NBIX’s average 12-month price target, according to analysts?
Based on analyst ratings, Neurocrine Biosciences’s 12-month average price target is 210.60.
    What is NBIX’s upside potential, based on the analysts’ average price target?
    Neurocrine Biosciences has 19.82% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NBIX a Buy, Sell or Hold?
          Neurocrine Biosciences has a consensus rating of Strong Buy which is based on 23 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Neurocrine Biosciences’s price target?
            The average price target for Neurocrine Biosciences is 210.60. This is based on 26 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $249.00 ,the lowest forecast is $165.00. The average price target represents 19.82% Increase from the current price of $175.77.
              What do analysts say about Neurocrine Biosciences?
              Neurocrine Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 26 Wall Streets Analysts.
                How can I buy shares of NBIX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.